Fig. 3.

CD3 and CD8 TILs density, and PD-L1 expression analyses among non-metastatics ASCC according to CRT treatment response. (A) Representative immunohistochemistry results for high and low CD3, CD8 and PD-L1 expression (up and down panels respectively); (B) Comparative analysis of immunological markers and response to treatment. CR: Complete Response, NCR: Non-Complete Response; (C) Logistic regression model showing the relationship between high or low PD-L1 expression levels based on CPS grading and the likelihood to achieve CR compared with PD-L1 negative tumors. (D) Box plot of CD3 and CD8 TIL density among high, low and PD-L1 negative cases.